Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol salt crossover study in persistent asthma
2009-010589-46Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indacaterol in persistent asthma and asthma (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline to trough FEV1 after 7 days of treatment. Started Apr 2009; status: completed.
02
Drugs
indacaterol
03
Conditions
persistent asthmaasthma
Beyond the preview
Go deeper on 2009-010589-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010589-46.